GLP-1 drugs started as antidiabetics. They are now reshaping obesity, cardiovascular disease, and more opening one of the largest new commercial frontiers in pharma. The patent landscape behind that shift is more complex than most investment models account for. We broke it all down patenting trends, technology clusters, key assignees, and a jurisdiction-by-jurisdiction remaining life analysis.
Which market do you think will see generic GLP-1 entry first? https://bit.ly/4dec8tx
#patseer #patents #patentlandscape #PatentPortfolio #aipatentsearch #Patentanalysis #PatentInsights #PatentDatabase #PatentAnalytics #GLP1
Comments